Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 1/20 | 0.34 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14402985 | 0.79 | ERN1 (0.34) | ERN1MCL1MAPTCA1CA2 | |
| SCHEMBL4978739 | 0.74 | CTSA (0.33) | MAPT | |
| SCHEMBL875044 | 0.72 | BACE1 (0.39) | SMN1; SMN2ALDH1A1LMNAHPGDCYP3A4 | |
| SCHEMBL5553479 | 0.71 | ALDH1A1 (0.41) | SMN1; SMN2MAPTALDH1A1L3MBTL1CYP3A4 | |
| SCHEMBL1620763 | 0.70 | ERN1 (0.36) | ERN1MAPTALDH1A1LMNAL3MBTL1 | |
| SCHEMBL8777267 | 0.70 | KCNH2 (0.35) | SMN1; SMN2CYP3A4HTT | |
| SCHEMBL22774158 | 0.69 | SMYD2 (0.32) | SMN1; SMN2CYP3A4HTT | |
| SCHEMBL5549739 | 0.69 | TACR1 (0.35) | SMN1; SMN2ALDH1A1LMNAHPGDCYP3A4 | |
| SCHEMBL4116949 | 0.69 | SMYD2 (0.31) | SMN1; SMN2CYP3A4HTT | |
| SCHEMBL30751030 | 0.69 | SMYD2 (0.33) | SMN1; SMN2CYP3A4HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080119518-A1 | 1-(Piperidin-4- Yl)-1H-Indole Derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-05-22 | — | — | US | disclosed |
| US-20080119518-A1 | 1-(Piperidin-4- Yl)-1H-Indole Derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-05-22 | — | — | US | disclosed |
| EP-1847535-A1 | 1-(PIPERIDIN-4-YL)-1H-INDOLE DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2007-10-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119518-A1 | 1-(Piperidin-4- Yl)-1H-Indole Derivatives | TPH1, HTR1D, HTR1B | ERN1 3091/4885MCL1 1129/4885SMN1; SMN2 3705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.